Education
About Us
Working with TipRanks
Follow Us
Shanghai Pharmaceuticals Holding Co Class H (HK:2607)
:2607
RESEARCH TOOLSreports
Total Valuation
Shanghai Pharmaceuticals Holding Co has a market cap or net worth of HK$64.67B. The enterprise value is HK$72.29B.
Market CapHK$64.67B
Enterprise ValueHK$72.29B
Share Statistics
Shanghai Pharmaceuticals Holding Co has 919,072,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding919,072,700
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Shanghai Pharmaceuticals Holding Co’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.47%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)4.47%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee5.57M
Profits Per Employee118.82K
Employee Count49,402
Asset Turnover1.24
Inventory Turnover6.28
Valuation Ratios
The current PE Ratio of Shanghai Pharmaceuticals Holding Co is 9.65. Shanghai Pharmaceuticals Holding Co’s PEG ratio is 0.47.
PE Ratio9.65
PS Ratio0.00
PB Ratio0.61
Price to Fair Value0.61
Price to FCF12.82
Price to Operating Cash Flow7.54
PEG Ratio0.47
Income Statement
In the last 12 months, Shanghai Pharmaceuticals Holding Co had revenue of 275.25B and earned 4.55B in profits. Earnings per share was 1.23.
Revenue275.25B
Gross Profit30.63B
Operating Income8.14B
Pretax Income8.02B
Net Income4.55B
EBITDA12.06B
Earnings Per Share (EPS)1.23
Cash Flow
In the last 12 months, operating cash flow was 5.99B and capital expenditures 0.00, giving a free cash flow of 7.95B billion.
Operating Cash Flow5.99B
Free Cash Flow7.95B
Free Cash Flow per Share8.65
Dividends & Yields
Shanghai Pharmaceuticals Holding Co pays an annual dividend of HK$0.087, resulting in a dividend yield of 4.78%
Dividend Per ShareHK$0.087
Dividend Yield4.78%
Payout Ratio35.02%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change-3.87%
50-Day Moving Average11.40
200-Day Moving Average11.91
Relative Strength Index (RSI)50.30
Average Volume (3m)4.61M
Important Dates
Shanghai Pharmaceuticals Holding Co upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend DateSep 17, 2024
Financial Position
Shanghai Pharmaceuticals Holding Co as a current ratio of 1.36, with Debt / Equity ratio of 69.84%
Current Ratio1.36
Quick Ratio1.05
Debt to Market Cap1.06
Net Debt to EBITDA1.00
Interest Coverage Ratio5.01
Taxes
In the past 12 months, Shanghai Pharmaceuticals Holding Co has paid 2.15B in taxes.
Income Tax2.15B
Effective Tax Rate0.27
Enterprise Valuation
Shanghai Pharmaceuticals Holding Co EV to EBITDA ratio is 4.64, with an EV/FCF ratio of 16.33.
EV to Sales0.20
EV to EBITDA4.64
EV to Free Cash Flow16.33
EV to Operating Cash Flow9.60
Balance Sheet
Shanghai Pharmaceuticals Holding Co has HK$45.03B in cash and marketable securities with ¥50.99B in debt, giving a net cash position of HK$5.96B billion.
Cash & Marketable SecuritiesHK$45.03B
Total Debt¥50.99B
Net CashHK$5.96B
Net Cash Per ShareHK$6.49
Tangible Book Value Per ShareHK$18.02
Margins
Gross margin is 10.79%, with operating margin of 2.96%, and net profit margin of 1.65%.
Gross Margin10.79%
Operating Margin2.96%
Pretax Margin2.91%
Net Profit Margin1.65%
EBITDA Margin4.38%
EBIT Margin3.50%
Analyst Forecast
The average price target for Shanghai Pharmaceuticals Holding Co is HK$13.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$13.45
Price Target Upside23.15% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast3.27%
EPS Growth Forecast12.87%